This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Despite adequate control of positive symptoms, many patients with schizophrenia suffer from severe cognitive deficits that limit their ability to realize optimal functional capacity. Medications that enhance dopaminergic activity in the prefrontal cortex may be ideal to improve cognition without worsening psychosis. Atomoxetine has been shown in pre-clinical studies to increase dopamine levels in prefrontal cortex but not in subcortical regions such as striatum and nucleus accumbens. Therefore, we believe that it may be extremely useful, when added to a stable regimen of antipsychotic medication, in enhancing cognition in patients with schizophrenia. In the proposed study, we will conduct baseline neurocognitive tests and measure activation of the prefrontal cortex by a working memory test during functional magnetic resonance imaging (fMRI) in patients with schizophrenia and schizoaffective disorder. Patients will then be randomized to receive either atomoxetine or placebo in addition to their regular dose of antipsychotic medication. The starting dose of atomoxetine will be 40 mg per day which will be increased to 40 mg bid after four weeks and then continued at this dose for the next four weeks. After four and eight weeks of treatment, repeat neurocognitive tests will be conducted and the fMRI will be repeated only after eight weeks of treatment.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
2M01RR000071-43
Application #
7380539
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2006-04-17
Project End
2007-02-28
Budget Start
2006-04-17
Budget End
2007-02-28
Support Year
43
Fiscal Year
2006
Total Cost
$6,434
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Grams, Morgan E; Sang, Yingying; Ballew, Shoshana H et al. (2018) Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int 93:1442-1451
Kattan, Meyer; Bacharier, Leonard B; O'Connor, George T et al. (2018) Spirometry and Impulse Oscillometry in Preschool Children: Acceptability and Relationship to Maternal Smoking in Pregnancy. J Allergy Clin Immunol Pract 6:1596-1603.e6
Coplan, Jeremy D; Webler, Ryan; Gopinath, Srinath et al. (2018) Neurobiology of the dorsolateral prefrontal cortex in GAD: Aberrant neurometabolic correlation to hippocampus and relationship to anxiety sensitivity and IQ. J Affect Disord 229:1-13
Altman, Matthew C; Whalen, Elizabeth; Togias, Alkis et al. (2018) Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. J Allergy Clin Immunol 142:1856-1866
Juraschek, Stephen P; Miller 3rd, Edgar R; Appel, Lawrence J (2018) Orthostatic Hypotension and Symptoms in the AASK Trial. Am J Hypertens 31:665-671
Chen, Teresa K; Appel, Lawrence J; Grams, Morgan E et al. (2017) APOL1 Risk Variants and Cardiovascular Disease: Results From the AASK (African American Study of Kidney Disease and Hypertension). Arterioscler Thromb Vasc Biol 37:1765-1769
Ku, Elaine; Gassman, Jennifer; Appel, Lawrence J et al. (2017) BP Control and Long-Term Risk of ESRD and Mortality. J Am Soc Nephrol 28:671-677
Anderegg, Nanina; Johnson, Leigh F; Zaniewski, Elizabeth et al. (2017) All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up. AIDS 31 Suppl 1:S31-S40
Gern, James E; Calatroni, Agustin; Jaffee, Katy F et al. (2017) Patterns of immune development in urban preschoolers with recurrent wheeze and/or atopy. J Allergy Clin Immunol 140:836-844.e7
Abdallah, Chadi G; Jackowski, Andrea; Salas, Ramiro et al. (2017) The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder. Neuropsychopharmacology 42:1739-1746

Showing the most recent 10 out of 869 publications